ReviewInternational journal of molecular sciences2024
Sepsis Biomarkers: Advancements and Clinical Applications-A Narrative Review.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Wearable Sweat Biosensors for Inflammatory Biomarkers (CRP, IL-6 and TNF-α): A Systematic Review of Analytical and Clinical Evidence.Biosensors · 2026Pooled it
- LINC02363: a potential biomarker for early diagnosis and treatment of sepsis.BMC immunology · 2025Pooled it
- Systemic immune-inflammation index and the short-term mortality of patients with sepsis: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Efficacy of blood copeptin level for the prediction of mortality of adult patients with sepsis: a meta-analysis.Frontiers in medicine · 2025Pooled it
- The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis.Military Medical Research · 2026Article
- Physiological Phenotypes in Comatose ICU Patients: A Retrospective Multidimensional Analysis.Diagnostics (Basel, Switzerland) · 2026Article
- Day-7 lactate-to-albumin ratio as a prognostic marker in sepsis patients requiring prolonged mechanical ventilation: a multicenter retrospective landmark analysis of the Korean Sepsis Alliance registry.Journal of thoracic disease · 2026Article
- Molecular Characterization and Clinical Outcomes ofChildren (Basel, Switzerland) · 2026Article
- The Role of Proenkephalin in Predicting Renal Dysfunction and Mortality in Septic Patients Admitted to the Emergency Department and Intensive Care Unit: A Narrative Review.Journal of personalized medicine · 2026Review
- An Inflammation-Adjusted Framework for Nutritional Assessment in Multimorbid Patients with Advanced Neurological Diseases.Medicina (Kaunas, Lithuania) · 2026Observational
- Critical Illness-Related Alterations in Plasma Phosphatidylcholine Species Reveal Selective Induction of PC 32:0.International journal of molecular sciences · 2026Article
- Hexosylceramide Species in the Blood Decline in Both COVID-19 and Non-COVID-19 Sepsis.Biomedicines · 2026Article
- Prognostic value of C-reactive protein to albumin ratio (CAR) for mortality in older adults with sepsis: Cohort study.Clinical medicine (London, England) · 2026Article
- Development and validation of an interpretable machine learning model for predicting sepsis risk in pleural effusion patients.Journal of thoracic disease · 2026Article
- Multi-omics insights into immunometabolic dysregulation in neonatal sepsis for precision medicine.Molecular biology reports · 2026Review
- Discriminating Post-Transplant Rejection from Infection by Detecting TCR-CD3 Oligomerization on Extracellular Vesicles Using a Ratiometric Caliper Probe.Journal of the American Chemical Society · 2026Article
- Clinical Performance of BIO-S and BIO-SC Composite Bioscores for 28-Day Mortality Stratification in Adults with Sepsis and Septic Shock.Biomedicines · 2026Article
- Association of early serial serum NLRP3 measurements with 28-day mortality in sepsis: a single-center retrospective landmark cohort study.BMC infectious diseases · 2026Article
- Diagnostic accuracy of PCT, IL-6, and MR-ProADM for early identification of sepsis in the emergency department.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Observational
- Early ΔNLR Outperforms Baseline Inflammatory Markers in Predicting Short-Term Outcomes in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sepsis is now defined as a life-threatening syndrome of organ dysfunction triggered by a dysregulated host response to infection, posing significant challenges in critical care. The main objective of this review is to evaluate the potential of emerging biomarkers for early diagnosis and accurate prognosis in sepsis management, which are pivotal for enhancing patient outcomes. Despite advances in supportive care, traditional biomarkers like C-reactive protein and procalcitonin have limitations, and recent studies have identified novel biomarkers with increased sensitivity and specificity, including circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2. These emerging biomarkers hold promising potential for the early detection and prognostication of sepsis. They play a crucial role not only in diagnosis but also in guiding antibiotic therapy and evaluating treatment effectiveness. The introduction of point-of-care testing technologies has brought about a paradigm shift in biomarker application, enabling swift and real-time patient evaluation. Despite these advancements, challenges persist, notably concerning biomarker variability and the lack of standardized thresholds. This review summarizes the latest advancements in sepsis biomarker research, spotlighting the progress and clinical implications. It emphasizes the significance of multi-biomarker strategies and the feasibility of personalized medicine in sepsis management. Further verification of biomarkers on a large scale and their integration into clinical practice are advocated to maximize their efficacy in future sepsis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.